Doxazosin (Cardura)

577  relevant articles (72 outcomes, 169 trials/studies) found for this Drug

Cardura; 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine; Alfamedin; Aliud Brand of Doxazosin Mesylate; Almirall Brand of Doxazosin Mesylate; Alpharma Brand of Doxazosin Mesylate; Alter Brand of Doxazosin Mesylate; Apo-Doxazosin; Apogepha Brand of Doxazosin Mesylate; Apotex Brand of Doxazosin Mesylate; AstraZeneca Brand of Doxazosin Mesylate; Azupharma Brand of Doxazosin Mesylate; Cantabria Brand of Doxazosin Mesylate; Cardular; Carduran; Carduran Neo; Ciclum Brand of Doxazosin Mesylate; Cinfa Brand of Doxazosin Mesylate; Combino Brand of Doxazosin Mesylate; Diblocin; Doxa-Puren; DoxaUro; Doxacor; Doxagamma; Doxamax; Doxatensa; Doxazomerck; Doxazosin AL; Doxazosin AZU; Doxazosin Apogepha; Doxazosin Heumann; Doxazosin Klast; Doxazosin Monohydrochloride; Doxazosin Stada; Doxazosin beta; Doxazosin findusFit; Doxazosin-Wolff; Doxazosin-ratiopharm; Doxazosina Alter; Doxazosina Cinfa; Doxazosina Combino Pharm; Doxazosina Geminis; Doxazosina Normon; Doxazosina Pharmagenus; Doxazosina Ratiopharm; Doxazosina Ur; Geminis Brand of Doxazosin Mesylate; Gen-Doxazosin; Genpharm Brand of Doxazosin Mesylate; Heumann Brand of Doxazosin Mesylate; Hexal Brand of Doxazosin Mesylate; Juta Brand of Doxazosin Mesylate; Jutalar; Kade Brand of Doxazosin Mesylate; Linden Brand of Doxazosin Mesylate; MTW Brand of Doxazosin Mesylate; MTW-Doxazosin; Merck dura Brand of Doxazosin Mesylate; Normon Brand of Doxazosin Mesylate; Novo-Doxazosin; Novopharm Brand of Doxazosin Mesylate; Pfizer Brand of Doxazosin Mesylate; Pharmagenus Brand of Doxazosin Mesylate; Progandol Neo; Q-Pharm Brand of Doxazosin Mesylate; Ratiopharm Brand of Doxazosin Mesylate; Solvay Brand of Doxazosin Mesylate; Stadapharm Brand of Doxazosin; TAD Brand of Doxazosin Mesylate; UK-33274; Uriduct; Wolff Brand of Doxazosin Mesylate; Wörwag Brand of Doxazosin Mesylate; Zoxan; betapharm Brand of Doxazosin Mesylate; ct-Arzneimittel Brand of Doxazosin Mesylate; doxazosin von ct; esparma Brand of Doxazosin Mesylate; findusFit Brand of Doxazosin Mesylate; ratio-Doxazosin; Apo Doxazosin; Doxa Puren; Doxazosin Wolff; Doxazosin ratiopharm; Gen Doxazosin; MTW Doxazosin; Mesylate, Doxazosin; Monohydrochloride, Doxazosin; Neo, Carduran; Novo Doxazosin; Q Pharm Brand of Doxazosin Mesylate; Ratiopharm, Doxazosina; UK 33274; UK33274; ct Arzneimittel Brand of Doxazosin Mesylate; ratio Doxazosin; Doxazosin Mesylate; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-

Relationship Network

Drug Context: Research Results

Experts

1.	Kirby, R S: 6 articles (01/2005 - 07/2000)
2.	Roehrborn, Claus G: 4 articles (11/2007 - 12/2003)
3.	Wykretowicz, Andrzej: 3 articles (03/2008 - 12/2007)
4.	Wysocki, Henryk: 3 articles (03/2008 - 12/2007)
5.	Guzik, Przemyslaw: 3 articles (03/2008 - 12/2007)
6.	Lepor, Herbert: 3 articles (11/2007 - 01/2003)
7.	Kusek, John W: 3 articles (11/2007 - 12/2003)
8.	Nyberg, Leroy M: 3 articles (11/2007 - 12/2003)
9.	Fogari, Roberto: 3 articles (04/2006 - 06/2005)
10.	Kaplan, Steven A: 3 articles (01/2006 - 12/2003)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/1991 - "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension" 08/16/1989 - "This unique combination of antihypertensive efficacy and favorable effect on blood lipid levels indicates that once-daily treatment with doxazosin holds considerable promise in the treatment of hypertension, both from the point of view of its antihypertensive efficacy and also from its primary preventative potential." 05/01/2000 - "These findings demonstrate that doxazosin add-on therapy is an effective, well-tolerated treatment strategy for patients with inadequately controlled hypertension." 01/01/1995 - "Thus, it can be concluded doxazosin is an effective and well tolerated treatment for BPH which appears to have additional benefits in the management of patients with concomitant hypertension." 10/01/1990 - "Doxazosin was well tolerated and was shown to be effective as monotherapy in mild and moderate hypertension" Order ALL the reference details at left...
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 06/10/2005 - "These findings, that demonstrate chronic doxazosin administration causes significant changes in the expression of several hundred genes in the rat prostate, may provide insight into the long-term efficacy of alpha1-AR antagonists in the treatment of benign prostatic hyperplasia." 09/01/1996 - "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." 03/01/1994 - "In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated" 01/01/1993 - "The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients" 10/01/2005 - "Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction." Order ALL the reference details at left...
3.	Heart Failure 07/01/2001 - "I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure" 10/01/2005 - "METHODS: A double-blind, randomized study was conducted on 30 patients with chronic congestive heart failure (NYHA III-IV), with cardiac index<2.5 l/minxm, and/or with pulmonary capillary wedge pressure>16 mm Hg. Of the 30 patients, 15 were treated with doxazosin and 15 with placebo, both adjuvant to stable oral therapy, which included a minimum of an ACE inhibitor and a diuretic" 04/01/2001 - "The doxazosin arm of the ALLHAT study was terminated by the data monitoring and safety board because the doxazosin-treated patients developed congestive heart failure at a greater rate than diuretic-treated patients" 01/01/1991 - "In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF)" 01/01/1991 - "Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study." Order ALL the reference details at left...
4.	Coronary Disease (Coronary Heart Disease) 05/01/1996 - "This study demonstrates that antihypertensive therapy with doxazosin can favorably affect coronary disease risk factors and reduce predicted coronary disease risk." 01/01/1991 - "According to the Framingham Heart Study equation, doxazosin produced a highly significant (p less than 0.001) 20% reduction in the calculated probability of developing coronary heart disease in 10 years" 03/01/2008 - "Doxazosin reduces blood pressure and additionally influences other risk factors of coronary heart disease" 05/01/1996 - "Mean predicted 5-year coronary disease risk was significantly reduced with doxazosin therapy by 14.7% in previously untreated patients (p < 0.0001) and by 1.7% in patients who were previously receiving antihypertensive therapy (p < 0.05)" 05/01/1996 - "The effects of doxazosin on office blood pressure, changes in lipid profiles, and theoretic coronary disease risk were studied" Order ALL the reference details at left...
5.	Syndrome 12/01/1998 - "The alpha1-adrenoceptor blocker, doxazosin, increases the coronary vasodilator reserve in patients with syndrome X. To study whether the augmentation is associated with clinical improvement in patients, we conducted a double-blind, placebo controlled, crossover study with doxazosin 1 to 4 mg once daily for 10 weeks in 16 patients with syndrome X (14 women and 2 men; mean +/- SD age 56+/-5 years)" 05/01/2007 - "Intraoperative floppy iris syndrome with doxazosin." 04/01/2007 - "Intraoperative floppy-iris syndrome with doxazosin." 01/01/2007 - "CONCLUSION: In patients with the metabolic syndrome, doxazosin treatment not only decreases platelet activity, as measured by a change in MPV, but also improves metabolic abnormalities" 10/01/1999 - "No differences were found between the effects of alpha1-blockade with doxazosin or those of placebo with respect to myocardial blood flow in syndrome X. The values obtained for myocardial blood flow and coronary vasodilator reserve for the patients were within the normal range" Order ALL the reference details at left...

Related Drugs and Biologics

1.	terazosine (terazosin)
2.	Atenolol (Tenormin)
3.	Finasteride (Propecia)
4.	Prazosin (Minipress)
5.	Lipids
6.	Glucose (Dextrose)
7.	Adrenergic Antagonists (Antiadrenergic Agents)
8.	Antihypertensive Agents (Antihypertensives)
9.	sildenafil (Viagra)
10.	tolterodine (Detrol)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Massage (Reflexology)
3.	Biofeedback (Psychology) (Biofeedback)
4.	Kidney Transplantation
5.	Prostatectomy (Retropubic Prostatectomy)